Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study

Autor: Smith, J, Bansi-Matharu, L, Cambiano, V, Dimitrov, D, Bershteyn, A, Van de Vijver, D, Kripke, K, Revill, P, Boily, M-C, Meyer-Rath, G, Taramusi, I, Lundgren, JD, Van Oosterhout, JJ, Kuritzkes, D, Schaefer, R, Siedner, MJ, Schapiro, J, Delany-Moretlwe, S, Landovitz, RJ, Flexner, C, Jordan, M, Venter, F, Radebe, M, Ripin, D, Jenkins, S, Resar, D, Amole, C, Shahmanesh, M, Gupta, RK, Raizes, E, Johnson, C, Inzaule, S, Shafer, R, Warren, M, Stansfield, S, Paredes, R, Phillips, AN, HIV Modelling Consortium

Publikováno v: The Lancet HIV, 10(4), e254-e265. Elsevier Ltd.
e265
e254

Background: Long-acting injectable cabotegravir pre-exposure prophylaxis (PrEP) is recommended by WHO as an additional option for HIV prevention in sub-Saharan Africa, but there is concern that its introduction could lead to an increase in integrase-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e7dd6628f0fcc01f3d8afaff868fc77
https://pure.eur.nl/en/publications/0ddb9996-8777-47ca-b5bb-83b46ba5d006

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.

Autor: Smith J; Institute for Global Health, University College London, London, UK., Bansi-Matharu L; Institute for Global Health, University College London, London, UK., Cambiano V; Institute for Global Health, University College London, London, UK., Dimitrov D; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Bershteyn A; Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA., van de Vijver D; Department of Viroscience, Erasmus Medical Centre, Rotterdam, Netherlands., Kripke K; Avenir Health, Takoma Park, MD, USA., Revill P; Centre for Health Economics, University of York, York, UK., Boily MC; MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK., Meyer-Rath G; Health Economics and Epidemiology Research Office (HE2RO), Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Taramusi I; National AIDS Council, Harare, Zimbabwe., Lundgren JD; Department of Clinical Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., van Oosterhout JJ; Partners in Hope, Lilongwe, Malawi; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA., Kuritzkes D; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA., Schaefer R; Global HIV, Hepatitis, and STIs Programmes, WHO, Geneva, Switzerland., Siedner MJ; Department of Medicine, Harvard Medical School, Boston, MA, USA; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Clinical Research Department, Africa Health Research Institute, Mtubatuba, South Africa., Schapiro J; National Hemophilia Center, Sheba Medical Center, Ramat Gan, Israel., Delany-Moretlwe S; Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Landovitz RJ; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; Center for Clinical AIDS Research and Education, University of California, Los Angeles, CA, USA., Flexner C; Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA., Jordan M; Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA., Venter F; Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Radebe M; Regional Office for Africa, WHO, Gauteng, South Africa., Ripin D; Infectious Diseases Program, Clinton Health Access Initiative, New York, NY, USA., Jenkins S; Infectious Diseases Program, Clinton Health Access Initiative, New York, NY, USA., Resar D; Infectious Diseases Program, Clinton Health Access Initiative, New York, NY, USA., Amole C; Infectious Diseases Program, Clinton Health Access Initiative, New York, NY, USA., Shahmanesh M; Institute for Global Health, University College London, London, UK; Clinical Research Department, Africa Health Research Institute, Mtubatuba, South Africa., Gupta RK; Clinical Research Department, Africa Health Research Institute, Mtubatuba, South Africa; Department of Medicine, University of Cambridge, Cambridge, UK., Raizes E; US Department of Health and Human Services, Centers for Disease Control, Atlanta, GA, USA., Johnson C; Global HIV, Hepatitis, and STIs Programmes, WHO, Geneva, Switzerland., Inzaule S; Global HIV, Hepatitis, and STIs Programmes, WHO, Geneva, Switzerland., Shafer R; Department of Medicine, Stanford University, Palo Alto, CA, USA., Warren M; AVAC, New York, NY, USA., Stansfield S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Paredes R; Department of Infectious Diseases, Irsi Caixa Institut de Recerca de la SIDA, Barcelona, Spain., Phillips AN; Institute for Global Health, University College London, London, UK. Electronic address: andrew.phillips@ucl.ac.uk.

Publikováno v: The lancet. HIV [Lancet HIV] 2023 Apr; Vol. 10 (4), pp. e254-e265. Date of Electronic Publication: 2023 Jan 12.